drugset / Trial / NCT03467867
A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, multicenter, Phase II study to investigate the efficacy and safety of venetoclax in combination with Rituximab/hyaluronidase human in participants with relapsed or refractory chronic lymphocytic leukemia (CLL).
Timeline
- Start
- 2018-04-26
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 1600 mg | Intravenous |
| Subject | Venetoclax | Small molecule | 400 mg | Oral |
| Background | rHuPH20 | Protein / enzyme biologic | 26800 iu | Subcutaneous |